Bosnalijek dd Sarajevo

Bosnalijek dd Sarajevo has a liquidity risk score of medium, with a current ratio of 1.61 and negative free cash flow of -2.55 million BAM. The company holds 10.7 million BAM in cash and equivalents, but its long-term debt of 53.1 million BAM exceeds its cash reserves, resulting in a net negative cash position. The debt-to-equity ratio of 0.27 suggests a relatively conservative capital structure, but the negative operating cash flow of -2.78 million BAM raises concerns about short-term liquidity.

The company's profitability is weak, with a return on equity of -2.5% and a return on assets of -1.59%. These metrics fall significantly below the industry median for pharmaceutical firms, which typically report positive ROE and ROA. The operating loss of 4.71 million BAM and net loss of 4.94 million BAM indicate a deteriorating financial performance.

Geographically, Bosnalijek dd Sarajevo is heavily concentrated in Bosnia and Herzegovina, with no disclosed international revenue streams. The company operates a single business segment, with no diversification across therapeutic areas or product lines. This lack of diversification increases exposure to local economic and regulatory risks.

The company's growth trajectory is negative, with a net loss in the latest reporting period and no indication of near-term improvement. The capital expenditure of -718,140 BAM suggests a reduction in investment, which may signal a strategic retrenchment or financial constraint. The outlook for the current fiscal year is uncertain, with no disclosed guidance on revenue or margin recovery.

The risk assessment highlights liquidity as a key concern, with a medium risk rating. The dilution risk is low, as the company has no dilutive securities outstanding and no recent equity issuance. However, the negative operating cash flow and net loss raise concerns about the company's ability to service its 53.1 million BAM in long-term debt.

Recent filings and transcripts are not available in the provided data, but the company's financial statements show a consistent pattern of declining profitability and liquidity. The absence of positive cash flow and the presence of a net loss suggest that the company may need to seek external financing or restructuring in the near term.

Free cash flow surged 208.7% year-over-year to 18.9 million BAM, demonstrating significant improvement in cash generation capabilities.

Net income grew 6.9% year-over-year to 15.2 million BAM, indicating sustained profitability despite operating income volatility.

Revenue expanded at a 6.7% compound annual growth rate over four years, showing consistent top-line growth trajectory.

Debt-to-equity ratio of 0.27 is below the pharmaceutical cohort median of 0.18, suggesting a relatively conservative capital structure.

Capital expenditure intensity is above the cohort median, potentially indicating strategic investments in future production capacity or efficiency.

High credit risk and medium liquidity risk flags suggest potential financial stability concerns and limited access to capital markets.